257 related articles for article (PubMed ID: 10750574)
21. Prevention of bone loss in paraplegics over 2 years with alendronate.
Zehnder Y; Risi S; Michel D; Knecht H; Perrelet R; Kraenzlin M; Zäch GA; Lippuner K
J Bone Miner Res; 2004 Jul; 19(7):1067-74. PubMed ID: 15176988
[TBL] [Abstract][Full Text] [Related]
22. Effects of alendronate on metacarpal and lumbar bone mineral density, bone resorption, and chronic back pain in postmenopausal women with osteoporosis.
Iwamoto J; Takeda T; Sato Y; Uzawa M
Clin Rheumatol; 2004 Oct; 23(5):383-9. PubMed ID: 15278749
[TBL] [Abstract][Full Text] [Related]
23. Early changes in biochemical markers of bone turnover predict bone mineral density response to antiresorptive therapy in Korean postmenopausal women with osteoporosis.
Kim SW; Park DJ; Park KS; Kim SY; Cho BY; Lee HK; Shin CS
Endocr J; 2005 Dec; 52(6):667-74. PubMed ID: 16410657
[TBL] [Abstract][Full Text] [Related]
24. [Alendronate in postmenopausal women with osteopenia and osteoporosis: effects on bone mineral density during treatment and after withdrawal].
Jiang Y; Li M; Xia W; Xing X; Yu W; Tian J; Meng X; Zhou X
Zhonghua Yi Xue Za Zhi; 2002 Sep; 82(18):1254-6. PubMed ID: 12425805
[TBL] [Abstract][Full Text] [Related]
25. A detailed assessment of alterations in bone turnover, calcium homeostasis, and bone density in normal pregnancy.
Black AJ; Topping J; Durham B; Farquharson RG; Fraser WD
J Bone Miner Res; 2000 Mar; 15(3):557-63. PubMed ID: 10750571
[TBL] [Abstract][Full Text] [Related]
26. Peripheral quantitative computed tomography is useful to monitor response to alendronate therapy in postmenopausal women.
Sawada K; Morishige K; Nishio Y; Hayakawa J; Mabuchi S; Isobe A; Ogata S; Sakata M; Ohmichi M; Kimura T
J Bone Miner Metab; 2009; 27(2):175-81. PubMed ID: 19152069
[TBL] [Abstract][Full Text] [Related]
27. Peripheral quantitative computed tomography (pQCT) is useful for monitoring bone mineral density of the patients who receive hormone replacement therapy.
Sawada K; Morishige K; Ohmichi M; Nishio Y; Yamamoto T; Hayakawa J; Mabuchi S; Isobe A; Sasaki H; Sakata M; Tasaka K; Murata Y
Maturitas; 2007 Apr; 56(4):343-9. PubMed ID: 17010541
[TBL] [Abstract][Full Text] [Related]
28. Distal radius fracture is an early sign of general osteoporosis: bone mass measurements in a population-based study.
Mallmin H; Ljunghall S
Osteoporos Int; 1994 Nov; 4(6):357-61. PubMed ID: 7696833
[TBL] [Abstract][Full Text] [Related]
29. Alendronate produces greater effects than raloxifene on bone density and bone turnover in postmenopausal women with low bone density: results of EFFECT (Efficacy of FOSAMAX versus EVISTA Comparison Trial) International.
Sambrook PN; Geusens P; Ribot C; Solimano JA; Ferrer-Barriendos J; Gaines K; Verbruggen N; Melton ME
J Intern Med; 2004 Apr; 255(4):503-11. PubMed ID: 15049885
[TBL] [Abstract][Full Text] [Related]
30. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
McClung M; Recker R; Miller P; Fiske D; Minkoff J; Kriegman A; Zhou W; Adera M; Davis J
Bone; 2007 Jul; 41(1):122-8. PubMed ID: 17468062
[TBL] [Abstract][Full Text] [Related]
31. Bone densitometry: a new, highly responsive region of interest in the distal forearm to monitor the effect of osteoporosis treatment.
Ravn P; Alexandersen P; Møllgaard A
Osteoporos Int; 1999; 9(4):277-83. PubMed ID: 10550443
[TBL] [Abstract][Full Text] [Related]
32. Comparison of alendronate and intranasal calcitonin for treatment of osteoporosis in postmenopausal women.
Downs RW; Bell NH; Ettinger MP; Walsh BW; Favus MJ; Mako B; Wang L; Smith ME; Gormley GJ; Melton ME
J Clin Endocrinol Metab; 2000 May; 85(5):1783-8. PubMed ID: 10843152
[TBL] [Abstract][Full Text] [Related]
33. Skeletal benefits of two years of alendronate treatment are similar for early postmenopausal Asian and Caucasian women.
Wasnich RD; Ross PD; Thompson DE; Cizza G; Yates AJ
Osteoporos Int; 1999; 9(5):455-60. PubMed ID: 10550466
[TBL] [Abstract][Full Text] [Related]
34. Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis.
Tucci JR; Tonino RP; Emkey RD; Peverly CA; Kher U; Santora AC
Am J Med; 1996 Nov; 101(5):488-501. PubMed ID: 8948272
[TBL] [Abstract][Full Text] [Related]
35. Association between Colles' fracture and low bone mass: age-based differences in postmenopausal women.
Kanterewicz E; Yañez A; Pérez-Pons A; Codony I; Del Rio L; Díez-Pérez A
Osteoporos Int; 2002 Oct; 13(10):824-8. PubMed ID: 12378372
[TBL] [Abstract][Full Text] [Related]
36. Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3-year randomized placebo-controlled trial.
Chevrel G; Schott AM; Fontanges E; Charrin JE; Lina-Granade G; Duboeuf F; Garnero P; Arlot M; Raynal C; Meunier PJ
J Bone Miner Res; 2006 Feb; 21(2):300-6. PubMed ID: 16418786
[TBL] [Abstract][Full Text] [Related]
37. Denosumab improves density and strength parameters as measured by QCT of the radius in postmenopausal women with low bone mineral density.
Genant HK; Engelke K; Hanley DA; Brown JP; Omizo M; Bone HG; Kivitz AJ; Fuerst T; Wang H; Austin M; Libanati C
Bone; 2010 Jul; 47(1):131-9. PubMed ID: 20399288
[TBL] [Abstract][Full Text] [Related]
38. Effects of odanacatib on BMD and safety in the treatment of osteoporosis in postmenopausal women previously treated with alendronate: a randomized placebo-controlled trial.
Bonnick S; De Villiers T; Odio A; Palacios S; Chapurlat R; DaSilva C; Scott BB; Le Bailly De Tilleghem C; Leung AT; Gurner D
J Clin Endocrinol Metab; 2013 Dec; 98(12):4727-35. PubMed ID: 24064689
[TBL] [Abstract][Full Text] [Related]
39. Alendronate in early postmenopausal women: effects on bone mass during long-term treatment and after withdrawal. Alendronate Osteoporosis Prevention Study Group.
Ravn P; Weiss SR; Rodriguez-Portales JA; McClung MR; Wasnich RD; Gilchrist NL; Sambrook P; Fogelman I; Krupa D; Yates AJ; Daifotis A; Fuleihan GE
J Clin Endocrinol Metab; 2000 Apr; 85(4):1492-7. PubMed ID: 10770187
[TBL] [Abstract][Full Text] [Related]
40. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.
Gallagher JC; Rosen CJ; Chen P; Misurski DA; Marcus R
Bone; 2006 Dec; 39(6):1268-75. PubMed ID: 16884968
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
